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ABSTRACT
Introduction: Tedizolid phosphate 200 mg,
once daily for 6 days, has recently been approved
for the treatment of patients with acute bacterial
skin and skin structure infections (ABSSSIs) in
several countries; however, clinical experience in
real-life settings is currently limited. Here, we
report on the use of tedizolid with an extended
treatment duration for complex and severe
ABSSSIs in real-world clinical settings.
Methods: Two patients with cellulitis and two
patients with surgical site infection (SSI), aged
26–60 years, were treated with tedizolid phos-
phate 200 mg, intravenous/oral (IV/PO) or IV
only, once daily at four different institutions.
Results: Two morbidly obese patients had non-
necrotizing, non-purulent severe cellulitis,
which were complicated by sepsis or systemic
inflammatory response syndrome plus myositis.
One female patient failed on first-line empiric
therapy with IV cefalotin, clindamycin and
imipenem (3–4 days), and was switched to IV/
PO tedizolid (7 ? 5 days). One male patient
received IV clindamycin plus IV/PO tedizolid
(5 ? 5 days), but clindamycin was discontinued
on Day 3 due to an adverse event. For both
patients, clinical signs and symptoms improved
within 72 h, and laboratory results were nor-
malized by Days 7 and 8, respectively. Two
other patients (one obese, diabetic female with
chronic hepatitis and chronic obstructive pul-
monary disease) had complicated SSIs occurring
10 days after hernia repair with mesh or
3 months after spinal fusion surgery with metal
implant. First patient with previous methicillin-
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resistant Staphylococcus aureus (MRSA) bac-
teremia received a 7-day tedizolid IV course
empirically. The second patient with culture-
confirmed MRSA infection received a 14-day IV
course. Both patients responded within 72 h,
and local and systemic signs normalized by end
of treatment. There were no reports of
thrombocytopenia.
Conclusion: Tedizolid phosphate 200 mg for
7–14 days was a favored treatment option for
patients with severe/complex ABSSSIs, and was
effective following previous treatment failure or
in late-onset infections.
Funding: Editorial assistance and the article
processing charges were funded by Bayer AG,
Berlin, Germany.
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INTRODUCTION
Acute bacterial skin and skin structure infec-
tions (ABSSSIs; i.e. cellulitis, erysipelas, wound
infection and major cutaneous abscess) are the
most frequently diagnosed clinical presenta-
tions of skin infections in the USA, Europe, Asia
and Russia [1–6], and present a huge burden on
healthcare systems [3], particularly when
patients have multiple comorbidities [6] and/or
complications [7].
Tedizolid phosphate is a novel oxazolidi-
none antibiotic, which is rapidly converted
in vivo to tedizolid, the active moiety, by non-
specific phosphatases [8, 9]. Tedizolid has high
in vitro activity against a range of Gram-positive
bacteria, including Streptococcus pyogenes, van-
comycin-resistant enterococci and methicillin-
resistant Staphylococcus aureus (MRSA) [10, 11].
Tedizolid phosphate 200 mg is available in
intravenous (IV) and oral (PO) formulations,
and has a high oral bioavailability (82–95%), a
convenient dosing regimen (once daily, irre-
spective of food) and a relatively short duration
of therapy (6 days) [8, 9, 12–14]. In two ran-
domized, double-blind, multicenter Phase 3
studies in patients with ABSSSIs, 6 days of
treatment with tedizolid phosphate 200 mg IV/
PO once daily was non-inferior to 10 days of
treatment with linezolid 600 mg IV/PO twice
daily [15–17]. Tedizolid phosphate was
approved for use in 2014 by the US Food and
Drug Administration and in 2015 by the Euro-
pean Medicines Agency, and is now also avail-
able for the treatment of ABSSSIs in several
countries outside the USA and Europe, includ-
ing Mexico and Singapore [18, 19], and for the
treatment of complicated skin and skin struc-
ture infections (cSSSIs) in Russia [20].
We report here the real-world experiences of
using tedizolid phosphate in patients with
complex ABSSSIs/cSSSIs, who would generally
not be included in typical Phase 3 clinical trials
because of the complex nature and severity of
their infections, and the likelihood of their
failure to meet trial inclusion criteria. We
believe that these cases extend knowledge on
the efficacy and tolerability of tedizolid phos-
phate in the real-life treatment of complex and
severe ABSSSIs/cSSSIs, including the use of
therapeutic courses longer than the 6 days used
in Phase 3 studies.
CASE PRESENTATIONS
Four patients with complex cases of ABSSSI were
treated with tedizolid phosphate 200 mg, once
daily (Table 1). Informed consent was obtained
by the treating physicians from each patient for
being included in the publication.
Case 1
A 46-year-old, morbidly obese [body mass index
(BMI): 46.1 kg/m2] woman developed contact
dermatitis due to second-degree burns. She had
bullae with clear fluid at the burn sites (Fig. 1a)
and developed rapid-onset cellulitis, which was
painful, erythematous and swollen (Fig. 1a).
Necrotizing infection was ruled out by imaging
(i.e., computed tomography scan, Doppler
ultrasound).
After presenting to her local hospital, she
was diagnosed with a non-purulent, non-
necrotizing, severe cellulitis, complicated by
hypovolemia and sepsis. Blood cultures proved
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Table 1 Overview of cases
Case 1 Case 2 Case 3 Case 4
Age
(years)/gender
46/female 38/male 60/female 26/male
Diagnosis Non-purulent, non-
necrotizing, severe
cellulitis on lower
extremity of right leg,
complicated by
hypovolemia and
sepsis
Non-purulent, non-
necrotizing, severe
cellulitis on lower
extremity of right leg,
complicated by SIRS
and myositis
Acute erythematous
surgical wound
infection
Erythematous, purulent
surgical wound
infection
Laboratory
results at the
time of
initiating
tedizolid
treatment
Elevated white blood
cell count
Elevated immature
neutrophil bands
Elevated blood urea
nitrogen
Elevated serum
creatinine level
Elevated white blood
cell count
Elevated C-reactive
protein level
Elevated serum
creatinine level
Elevated creatine kinase
level
Elevated white blood cell
count
Elevated immature
neutrophil bands
Elevated hepatic enzyme
levels
Elevated blood urea
nitrogen
Elevated white blood cell
count
Elevated immature
neutrophil bands
Platelet count (9 109/
L) changes:
Before treatment: 192
During IV treatment:
254
At IV/PO switch: 299
Platelet count (9 109/
L) changes:
Before treatment: 230
During IV treatment:
200
At IV/PO switch: 230
Platelet count (9 109/
L) changes:
Before treatment: 296
During IV treatment:
320
After IV treatment: 324
Platelet count (9 109/
L) changes:
Before treatment: 235
During IV treatment:
260
After IV treatment: 240
Microbiology
testing
Negative blood culture;
no sample was taken
from primary ABSSSI
site
Negative blood culture;
no sample was taken
from primary
ABSSSI site
Hemorrhagic ﬂuid from
wound was collected
for culture and MRSA
was conﬁrmed
MRSA was reported to
be susceptible to
vancomycin,
daptomycin, linezolid,
rifampicin, fusidic acid,
and resistant to
oxacillin, cefoxitin,
ceftriaxone, ceftaroline,
ciproﬂoxacin
Purulent exudate from
wound was collected
for culture and MRSA
was conﬁrmed, with
elevated vancomycin
MIC = 2 lg/mL
MRSA was reported to
be susceptible to
vancomycin, linezolid;
no information is
available on
daptomycin,
ceftaroline, or
rifampicin
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Table 1 continued
Case 1 Case 2 Case 3 Case 4
Medical history Obesity (BMI: 46.1 kg/
m2)
Obesity (BMI: 59.4 kg/
m2), tinea pedis and
obstructive sleep
apnea
Obesity (BMI: 34.0 kg/
m2), type 2 diabetes
mellitus, COPD,
hepatitis, renal
impairment
Previous surgery for
acute necrotizing
pancreatitis; MRSA
bacteremia
None
Prior antibiotics
(if any)
First-generation
cephalosporin,
clindamycin and
imipenem
None Vancomycin None
Form of
treatment
Tedizolid phosphate
200 mg IV, QD,
7 days ? 200 mg PO,
QD, 5 days
Tedizolid phosphate
200 mg IV, QD,
5 days ? 200 mg
PO, QD, 5 days
Tedizolid phosphate
200 mg IV, QD,
7 days
Tedizolid phosphate
200 mg IV, QD,
14 days
Reason for
using
tedizolid
Presence of morbid
obesity, presence of
rapidly spreading
cellulitis after lack of
response to initial
empiric therapy and
reduction in platelet
count, and high risk
of MRSA; tedizolid
has greater potency
than linezolid against
MRSA
Presence of morbid
obesity and
comorbidities,
patient expressed
preference for once-
daily therapy with
ongoing GI
symptoms, and high
risk of MRSA;
tedizolid has greater
potency than
linezolid against
MRSA
Presence of obesity,
comorbidities,
ongoing renal and
hepatic abnormalities,
and previous
vancomycin treatment
and MRSA bacteremia
Elevated vancomycin
MIC of conﬁrmed
MRSA, extended
duration of treatment
(e.g., weeks) was
anticipated
Concomitant
antibiotics
None Clindamycin None None
Any adverse
event
None reported Rash (imputed to
clindamycin)
None reported None reported
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to be negative; no specimens were taken from
the primary ABSSSI site.
The patient was hospitalized and, on admis-
sion, was found to have an elevated white blood
cell (WBC) count (12.2 9 109/L). Empiric treat-
ment comprised a first-generation cephalos-
porin (i.e., cefalotin), clindamycin and
imipenem, all administered IV. The patient
showed no signs of improvement during
empiric treatment and the WBC count
increased progressively, reaching 41.3 9 109/L
within 3 days, with corresponding serum levels
of creatinine, blood urea nitrogen (BUN) and
procalcitonin of 1.2 mg/dL, 98.0 mg/dL and
1.3 ng/mL, respectively. Due to the lack of
response to empiric therapy, the rapidly
spreading cellulitis and the high local
endemicity of MRSA (* 50%), the antibiotic
regimen was changed to tedizolid phosphate
200 mg IV once daily for 7 days while the
patient remained in hospital. She responded to
therapy, with cessation of lesion spread within
72 h and normalization/improvement of labo-
ratory results by Day 5 of IV tedizolid treatment
(WBC: 20.5 9 109/L; serum creatinine: 0.6 mg/
dL, serum BUN: 43.0 mg/dL, procalcitonin:
0.2 ng/mL). Following IV treatment, the patient
was discharged and, due to the severity of the
primary infection, was treated for a further
5 days with tedizolid phosphate 200 mg PO
once daily. After 2 weeks of follow-up, skin
lesions had healed. No adverse event occurred
and the platelet count improved with tedizolid
treatment following the initial decrease
(Table 1).
Case 2
A 38-year-old man presented with rapidly
expanding, painful, erythematous non-puru-
lent cellulitis on the lower extremity of his right
leg. He had a very high fever [body temperature
(BT): 39.4 C], tachycardia (110 beats/min) and
relatively low blood pressure (105/60 mmHg),
consistent with systemic inflammatory
response syndrome (SIRS), and accompanied by
nausea, vomiting and diarrhea. No crepitus was
observed. His medical history included tinea
pedis and obstructive sleep apnea secondary to
morbid obesity (BMI: 59.4 kg/m2).
Non-necrotizing, severe cellulitis was diag-
nosed, complicated by myositis. No specimen
was taken from the primary ABSSSI site, due to
the lack of purulence, and blood cultures were
negative. Laboratory test results confirmed sys-
temic infection with acute renal impairment
and muscle involvement: WBC count
18.0 9 109/L, C-reactive protein (CRP) 285 mg/
dL, serum creatinine 1.5 mg/dL and creatine
kinase (CK): 624 U/L. Due to a high suspicion of
beta-hemolytic streptococci and the risk of
community-acquired MRSA (the patient had
recently travelled to Australasia), the patient
was treated empirically with tedizolid phos-
phate 200 mg IV once daily for 5 days, followed
Table 1 continued
Case 1 Case 2 Case 3 Case 4
Outcome Cessation of lesion
spread within
2–3 days; laboratory
results normal or
improved by Day 7
Cessation of lesion
spread and reduced
pain by Days 2–3;
laboratory
parameters improved
by Day 8
Reduction in erythema
by Days 2–3; no
edema, erythema or
induration by end of
therapy
Improved signs and
symptoms within
2–3 days, with
systemic signs
appearing normal at
end of therapy.
Wound was healed
5 weeks later
ABSSSI acute bacterial skin and skin structure infections, BMI body mass index, COPD chronic obstructive pulmonary
disease, GI gastrointestinal, IV intravenous, MIC minimum inhibitory concentration, MRSA methicillin-resistant Staphy-
lococcus aureus, PO oral, QD once daily, SIRS systemic inﬂammatory response syndrome
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by tedizolid PO for 5 more days as an outpa-
tient. Clindamycin 900 mg, q8h, was also pre-
scribed but discontinued due to an adverse
event (rash on Day 3). The patient responded
within 72 h of antibiotic therapy, with cessation
of lesion spread and a reduction in pain. Labo-
ratory parameters, including WBC count, CRP,
serum creatinine and CK levels, improved
markedly, and were almost within normal lim-
its by Day 8 (WBC count: 10.0 9 109/L; CRP:
12 mg/dL; serum creatinine: 1.0 mg/dL; CK:
normal). The patient remained well and was
discharged after 2 weeks of outpatient follow-
up. No adverse event occurred and the platelet
count remained within the normal range dur-
ing tedizolid treatment (Table 1).
Case 3
A 60-year-old woman, who underwent an elec-
tive hernia repair with mesh placement, devel-
oped a surgical site infection on Day 10 post-
surgery (Fig. 1b). The patient had received
thromboprophylaxis with enoxaparin 40 mg
subcutaneously once daily for 7 days following
surgery. She had multiple comorbidities,
including obesity (BMI: 34.0 kg/m2), type 2
diabetes mellitus controlled by metformin,
chronic obstructive pulmonary disease, chronic
hepatitis, and mild renal impairment. The
patient had previously been hospitalized with
acute necrotizing pancreatitis (for which she
underwent omentobursostomia), complicated
by MRSA bloodstream infection, which was
treated with vancomycin. Her acute, erythe-
matous wound infection at presentation
showed edema and induration and was accom-
panied by pain and a slight elevation of BT but
she remained subfebrile.
Laboratory results revealed systemic inflam-
mation (WBC count: 18.0 9 109/L; immature
neutrophil bands: 29%), but not SIRS, elevated
hepatic enzyme levels (alanine aminotransferase,
aspartate aminotransferase, bilirubin) attributed
to ongoing hepatitis, and mildly elevated BUN
level (18.8 mg/dL). Surgical debridement was
performed on the day of diagnosis, with drainage
of * 300 mL of hemorrhagic opaque fluid, a
sample of which was sent for culture.
Given the presence of MRSA risk factors (i.e.,
previous MRSA bacteremia, previous hospital-
ization), comorbidities, ongoing renal impair-
ment and previous vancomycin treatment, the
Fig. 1 Presentation of cellulitis in Case 1 (a), and wound
infection in Case 2 (b) and Case 3 (c)
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decision was taken to treat the patient empiri-
cally with tedizolid phosphate 200 mg IV once
daily. She responded to therapy, with a decrease
in erythema by Days 2–3 and a normalization of
WBC count (9.0 9 109/L) and immature neu-
trophil bands (10%), at which point the wound
fluid was reported as culture positive for MRSA.
After 7 days of tedizolid phosphate therapy,
edema, erythema and induration had resolved
and renal laboratory parameters were normal.
There was no adverse event reported and no
thrombocytopenia was reported (Table 1).
Case 4
A 26-year-old previously healthy male had a
serious motorbike accident, resulting in frac-
tures to L5–S1 vertebrae that required immedi-
ate posterior spinal fusion surgery. Three
months following this surgery, he re-presented
with a painful, erythematous, purulent infec-
tion of the spinal wound. Fever (BT: 39.3 C),
elevated WBC count (16.5 9 109/L) and high
immature neutrophil bands (17%) were markers
and signs of systemic inflammation. The patient
was diagnosed as having a deep incisional sur-
gical wound infection. There was no definitive
clinical or radiological evidence of concurrent
osteomyelitis, although this was considered.
Culture and susceptibility testing of a sample
of the purulent exudate yielded MRSA with an
elevated vancomycin minimum inhibitory
concentration (MIC) of 2 lg/mL. Vancomycin
MIC was obtained by VITEK-2 automated test-
ing method which was confirmed by E test, and
this MRSA isolate was reported by the microbi-
ologist as susceptible to vancomycin and
linezolid.
The wound was debrided (Fig. 1c) and closed
using vacuum assistance, and the patient was
treated with tedizolid phosphate 200 mg IV
once daily for 14 days. Signs and symptoms
improved (BT: 37.3 C; WBC: 12.5 9 109/L;
immature neutrophil bands: 12%) within
2–3 days. By the end of therapy (Day 15), all
systemic signs of infection had resolved (BT:
36.3 C; WBC: 6.3 9 109/L; immature neu-
trophil bands: 4%) and antibiotic therapy was
stopped. The wound healed completely by
Week 5. Tedizolid was well tolerated and no
thrombocytopenia was reported (Table 1).
DISCUSSION
This case series describes how extended therapy
with tedizolid phosphate was successful in
treating severe cellulitis/myositis and wound
infections in patients with complex conditions.
Cellulitis is a very common ABSSSI diagnosis,
accounting for between 45% and 80% of hos-
pitalized ABSSSI/cSSSI cases globally [1, 3]. In
the UK, over 65% of cellulitis cases are severe
and require hospitalization for IV antibiotics
[4], with the majority (i.e., 90%) occurring on
the lower extremities [4, 5], as in the cases
reported here. A microbiological diagnosis is
frequently not achieved for cellulitis, particu-
larly in non-purulent presentations, and cover-
age mainly for Streptococcus pyogenes, and
possibly S. aureus (including MRSA in endemic
settings), is necessary, as these are the most
common causes of such infections [21]. Multi-
ple comorbidities, such as obesity, diabetes,
renal impairment and vascular/cardiac disease,
may increase the risk of cellulitis treatment
failure [22]. These conditions can cause lower
extremity edema, masking signs and symptoms
of cellulitis and leading to underestimation of
the severity of the condition [22].
Management of wounds require attention if
a patient shows clinical signs and symptoms of
infection and becomes systemically unwell [23].
Wound infections require the combination of
surgical debridement, antibiotic therapy and
appropriate local wound care because an infec-
tion delays wound healing. Predisposing host
factors for the development of post-surgical
infections (e.g., diabetes, poor circulation, and
immunosuppression) may overlap with those
that might delay wound healing [24]. In these
infections, the most likely causative pathogens
include S. aureus, although Gram-negative bac-
teria may also cause infections [25]. Considera-
tion of MRSA is necessary in countries with a
high prevalence; for example, MRSA preva-
lence * 50% is reported in Russia and Mexico
and 12–30% in Singapore [26–29], although
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much lower rates are seen in most European
countries [30].
Of note, the cases described in this case series
were complex due to the presence of compli-
cating factors such as SIRS, myositis, or even
sepsis, a condition that is frequently excluded
from ABSSSI Phase 3 trials because the increased
associated morbidity and mortality may con-
found the assessment of antibiotic effectiveness
[15, 16, 31]. Furthermore, patients with metal
implants are normally expected to require a
long course (up to 6–8 weeks) of antibiotic
treatment [32]; therefore, such cases would not
be included in Phase 3 trials. Complicating
factors similar to these present in these four
cases may allow inclusion into open-label, post-
approval, Phase 4 studies.
Antibiotic selection for the empiric treat-
ment of cellulitis and wound infections is
challenging. For patients with an ABSSSI due to
methicillin-susceptible S. aureus or streptococci,
a beta-lactam, a tetracycline, or clindamycin
would be recommended empirically as first-line
therapy [23], which were selected as empiric
therapies for our non-purulent cellulitis cases.
However, a suspicion of MRSA as the cause of an
ABSSSI is warranted when a patient fails on first-
line beta-lactam therapy and/or any risk factor
is present (e.g., high local prevalence, previous
MRSA infection or colonization, previous hos-
pitalization or surgery) such as in our cellulitis
cases [33]. Furthermore, the culture results from
exudate samples confirmed MRSA in our cases
of wound infection. Guidelines recommend the
use of vancomycin (plus piperacillin/tazobac-
tam) for severe cases of non-necrotizing cel-
lulitis [23] and for wound infection due to
confirmed MRSA [23]. Vancomycin treatment
can be problematic for obese or morbidly obese
patients, like most of our patients, due to its
dosing and exposure variability, and for those
with renal disease, who are at an increased risk
of adverse events due to elevated trough levels
[34, 35]. Of note, the risk of treatment failure
during vancomycin treatment is increased
when vancomycin MIC is reported as C 1.5 lg/
mL (i.e., confirmed MRSA with elevated van-
comycin MIC in Case 4) [36]. Daptomycin has a
very high potency against Gram-positive
ABSSSI/cSSSI pathogens. However, its use is not
recommended in patients with elevated CK
levels (as reported in Case 2) because it may
further delay tissue repair in soft tissue infec-
tions [23, 35], or in cases with elevated van-
comycin MIC (as reported in Case 4) due to
potential cross-resistance with vancomycin
[37, 38].
When a glycopeptide antibiotic seems
unsuitable, linezolid is frequently used for the
treatment of skin infections because it has high
potency against most causative Gram-positive
pathogens and has good skin and soft tissue
penetration [39]. The dosing of linezolid in
obese or morbidly obese [39] patients, and in
patients with renal [40] or hepatic [41] impair-
ment, has recently been queried. Thus, thera-
peutic monitoring for linezolid was recently
recommended to maintain its trough levels
between 2 and 8 mg/mL [39]. The most fre-
quently associated adverse reactions with line-
zolid treatment are gastrointestinal (GI) side
effects and thrombocytopenia [42]. These
adverse events may emerge as early as within
10 days and, furthermore, the risk of thrombo-
cytopenia is increased with prolonged duration
[15–17, 43]. These limiting factors were present
in three of the four presented cases (Case 1:
decreasing platelet count, Case 2: GI symptoms,
Case 3: renal and hepatic impairment, and
thromboprophylaxis with heparin), while in
Case 4, the treating surgeon excluded this
antibiotic due to an anticipated prolonged
duration and an increased risk of thrombocy-
topenia, respectively.
Tedizolid phosphate was selected for the
cases reported here because of its high in vitro
potency against Gram-positive bacteria
[10, 11, 44], including MRSA and streptococci.
It has a good penetration into skin and soft
tissue [45], a very high oral bioavailability
allowing equivalent dosing when switching
from IV to PO therapy [9, 12, 13], and conve-
nient once-daily dosing [8, 9, 12, 13]. In addi-
tion, unlike some antibiotics, such as
vancomycin, daptomycin or ceftaroline, tedi-
zolid phosphate does not require dose adjust-
ment in special populations, including the
elderly, the obese and morbidly obese, and
patients with renal or hepatic impairment
[14, 46–49]. In trials, tedizolid phosphate IV/PO
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once daily for 6 days demonstrated comparable
efficacy to linezolid IV/PO twice daily for
10 days in patients with cellulitis, major cuta-
neous abscess and wound infection, and similar
clinical cure rates were observed in subgroups of
patients, including those with higher BMI or
moderate/severe renal impairment and the
elderly [15–17]. Furthermore, irrespective of the
presence or absence of parameters related to
infection severity (i.e., fever, SIRS, immature
neutrophil count, severe pain, or elevated WBC
count), high clinical success rates were achieved
in patients treated with tedizolid phosphate
[50]. All four patients reported in our case series
responded to tedizolid therapy within 48–72 h
with cessation of lesion spread, detectable re-
duction in erythema, lack of fever, reduction in
pain and/or improvement of laboratory param-
eters. They had sustained improvement of signs
and symptoms at the end of therapy and were
considered to have achieved clinical cure at
later follow-up.
In the severe ABSSSI cases reported here,
physicians extended the duration of tedizolid
phosphate therapy beyond 6 days (i.e. 7–
14 days). For the patient with spinal fusion
surgery and subsequent wound infection caused
by MRSA (Case 4), antibiotic treatment was
initially anticipated to take several weeks. As
prolonged duration of linezolid therapy increa-
ses the risk of anemia or thrombocytopenia
[42], an antibiotic with lower myelotoxicity is
preferred for extended treatment durations. The
objective was to cure the infection, and to pre-
vent re-operation and removal of the metal
instrument because re-operation is necessary in
a large proportion of such patients due to MRSA
infection [51]. Furthermore, surgical patients
with renal impairment who require thrombo-
prophylaxis with low-molecular weight heparin
following surgery (Case 3) have an increased
risk of heparin-induced thrombocytopenia and
are ineligible for treatment with MRSA antibi-
otics documented to cause thrombocytopenia,
such as linezolid [52–54]. Tedizolid phosphate
200 mg once-daily administration is associated
with a significantly lower risk of thrombocy-
topenia versus linezolid 600 mg twice-daily
administration for up to 21 days in healthy
individuals [55], and in ABSSSI patients [56],
another crucial factor that contributed to the
antibiotic selection in patients with wound
infections. Of note, no hematological (or other)
side effects had been reported for these complex
patients with tedizolid as documented by
maintained normal levels of platelet count
during and after treatment.
The duration of therapy is not usually deci-
ded at the time of antibiotic selection, instead it
becomes clearer within 48–72 h [57]. For
patients with cellulitis, the effective durations
of IV therapy and total therapy are not well
characterized [58, 59]. In general, IV therapy for
5–6 days is typical in clinical practice [58].
Within 2–3 days, patients may respond to
antibiotic therapy with (1) a cessation of lesion
spread, (2) an improvement of local inflamma-
tion, (3) a reduced leukocyte count, or (4) an
improved CRP level [57], although, to achieve
clinical response/improvement, antibiotic esca-
lation may be necessary [57]. An analysis of
patients treated with tedizolid phosphate or
linezolid in the ESTABLISH studies suggested
that the lack of clinical response (i.e.,\ 20%
reduction in lesion size) to treatment within
48–72 h is not predictive of clinical failure at the
post-treatment evaluation visit or test-of-cure
visit [60]. In such complex cases as these
reported here, the clinical assessment of the
patients should be conducted at the later stage.
In patients with wound infections, when MRSA
is confirmed or is highly suspected due to the
presence of risk factors (e.g., history of MRSA)
when pathogen isolation is not feasible, tedi-
zolid phosphate 200 mg once daily for 6 or
7 days appears to be an appropriate treatment.
Treatment duration can be extended at the
discretion of the treating physician if sepsis,
SIRS or other complications are present, or if
there is a risk of relapse. In the series of severe
ABSSSI cases reported here, tedizolid phosphate
was efficacious and well tolerated when
administered at an extended treatment dura-
tion of up to 14 days.
CONCLUSION
In conclusion, the good efficacy and safety
profile of tedizolid phosphate seen in these
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cases, with a treatment duration extended up to
14 days (beyond the approved 6 days), make it a
valuable treatment choice for patients with
severe ABSSSIs, including complex cases with
prior treatment failure or late-onset infections.
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